Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 4/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30732668 | 0.85 | PDK1 (0.38) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL509358 | 0.80 | PDK1 (0.59) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL5560259 | 0.80 | PDK1 (0.59) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL15909553 | 0.80 | PDK1 (0.59) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL946229 | 0.80 | PDK1 (0.35) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL16797367 | 0.79 | PDK1 (0.41) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL19056428 | 0.79 | PDK1 (0.41) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL17791708 | 0.79 | PDK1 (0.41) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL570641 | 0.79 | PDK1 (0.41) | PDK1PDK2PDK3CA12CA1 | |
| SCHEMBL19056488 | 0.79 | PDK1 (0.41) | PDK1PDK2PDK3CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710054-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-04-29 | — | — | US | disclosed |
| EP-2170906-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-04-03 | — | — | EP | disclosed |
| US-20130079330-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2013-03-28 | — | — | US | disclosed |
| US-8338592-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8168634-B2 | Thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20110003785-A1 | Fused Thiazole Derivatives As Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2011-01-06 | — | — | US | disclosed |
| US-20100298310-A1 | Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | US | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003785-A1 | Fused Thiazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, MAP4K2 | PDK1 95/4885PDK2 104/4885PDK3 183/4885 |
| US-20130079330-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, MAP4K2 | PDK1 95/4885PDK2 104/4885PDK3 183/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | PDK1 75/4885PDK2 97/4885PDK3 156/4885 |
| US-20100298310-A1 | Thiazole Derivatives as Kinase Inhibitors | TEC, BTK, PI4KA | PDK1 144/4885PDK2 179/4885PDK3 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.